ArticleMolecular neurobiology2026
Mitochondrial-Inflammatory Axis Dysregulation Triggers Disulfidptosis and the Multifaceted Protective Mechanism of Bisphenol A Following Spinal Cord Injury.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) often leads to significant neurological impairment and poses a substantial therapeutic challenge, with disulfidptosis recently identified as a potential mechanism exacerbating such pathologies. This study examined the role of bisphenol A (BPA) in modulating key genes and metabolites associated with disulfidptosis in the context of SCI. Utilizing a murine SCI model, we established three cohorts: a sham control group, an SCI group, and an SCI group treated with BPA. Comprehensive assessments, including locomotor recovery analysis using the Basso Mouse Scale, gait analysis, histopathological evaluations via hematoxylin-eosin and Nissl staining, and integrated transcriptomic and metabolomic profiling, were conducted. BPA administration significantly improved locomotor recovery and mitigated histopathological alterations, with Ndufs1, Ndufa11, and Ndufb10 were identified as pivotal genes and leukotriene B4 and prostaglandin B2 emerged as crucial metabolites. Notably, these genes were intricately linked to the oxidative phosphorylation pathway and exhibited positive intercorrelations, whereas the metabolites were enriched within the arachidonic acid metabolism pathway. As the injury progressed, key gene expression diminished, whereas metabolite concentrations increased. BPA treatment effectively reversed these trends. Collectively, these findings indicate that BPA protects against SCI by disrupting a harmful feedback loop involving mitochondrial dysfunction and inflammatory activation, thus countering disulfidptosis and fostering an environment conducive to neural regeneration, underscoring its potential in SCI management.
Indexed as
Identifiers
42201472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.